The Defender’s Big Pharma Watch delivers the latest headlines related to pharmaceutical companies and their products, including vaccines, drugs, and medical devices and treatments. The views expressed in the below excerpts from other news sources do not necessarily reflect the views of The Defender. Our goal is to provide readers with breaking news that affects human health and the environment.

In the Lab: An Mpox mRNA Vaccine That’s Outperforming Its Old-School Predecessor
Medical Xpress reported:

The recent global mpox outbreak trained a bright spotlight on the need for safe and effective Orthopoxvirus vaccines, especially in light of continuously looming zoonotic threats and the potential for these pathogens to spread rapidly worldwide.

Now, a collaborative group of U.S. scientists is testing a candidate mRNA mpox nanoparticle vaccine with the hope of developing an immunization that is superior to the current mpox shot.

The research team mostly hails from the private and federal institutions that produced one of the highly successful COVID mRNA vaccines: Moderna Inc., in Cambridge, Mass., and the National Institute of Allergy and Infectious Diseases (NIAID) in Bethesda, Md. The new study also included collaboration with the United States Army Medical Research Institute of Infectious Diseases (USAMRIID) in Fort Detrick Md.

Writing in Science Translational Medicine, the researchers say the aim of the new mRNA vaccine for mpox is to have a shelf-ready inoculation in the event of a future outbreak. Having a vaccine in hand, they say, alleviates scrambling to figure out what might work most effectively as cases mount and doctors ask for the best immunization strategy to ward off additional infections.

Posted in

Iron Will

Leave a Comment

You must be logged in to post a comment.